The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ...

Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.

Eli Lilly and CVS Caremark both denied the allegations in statement to Forbes, with Eli Lilly arguing the lawsuit “ignores that anyone is eligible to purchase their monthly prescription of ...

Eli Lilly (LLY) shares slid at the open despite topping first quarter estimates, ... Eli Lilly's Q1 win outweighed by Novo's CVS deal. Yahoo Finance . Thu, May 1, 2025, 10:09 AM. In This Article: ...

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...

Derica Rice, a longtime Eli Lilly chief financial officer, is set to take over at CVS Caremark on March 30, according to an internal CVS memo reviewed by The Wall Street Journal. Mr.

Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.